Sangamo Therapeutics Reports Q1 Loss, Reiterates Going Concern, and Confirms Nasdaq Delisting
SGMO sits 36% above its 52-week low of $0.1 on light trading volume (0.2× avg).
Summary
Sangamo Therapeutics reported a $31.0 million net loss in Q1 2026, with cash only sufficient into Q3 2026, reiterating its going concern warning and confirming its delisting from Nasdaq to OTCQB.
Key Events · Financing and Capital Events · SGMO
-
Going Concern Warning Reiterated
Management believes substantial doubt exists about the company's ability to continue as a going concern, with cash and cash equivalents of $27.6 million estimated to meet liquidity requirements only into Q3 2026. The company is exploring options including ceasing operations, liquidating assets, or seeking bankruptcy protection.
-
Nasdaq Delisting Confirmed
The company's common stock was suspended from trading on Nasdaq on May 5, 2026, and now trades on the OTCQB Venture Market due to failure to meet minimum bid price requirements. An appeal hearing is set for June 9, 2026, but the trading suspension remains.
-
Significant Q1 2026 Net Loss
Sangamo Therapeutics reported a net loss of $31.0 million for the three months ended March 31, 2026, against minimal revenues of $1.4 million, highlighting ongoing operational losses.
-
Dilutive Financing in Q1 2026
The company raised $22.8 million in net proceeds from an underwritten offering of common stock and warrants, and an additional $3.7 million from an at-the-market (ATM) offering during Q1 2026. This financing included repricing 23.8 million warrants from $1.00 to $0.4719, indicating significant concessions.
Analysis · SGMO · Life Sciences
This quarterly report confirms Sangamo Therapeutics' severe financial distress, with a net loss of $31.0 million in Q1 2026 and cash and cash equivalents of only $27.6 million. The company explicitly reiterates its going concern warning, stating that current cash will only last into Q3 2026, and warns of potential cessation of operations or bankruptcy. The report also confirms the actual delisting from Nasdaq and subsequent trading on the OTCQB Venture Market, a significant negative event for liquidity and investor confidence. Despite recent dilutive financing efforts totaling over $26 million in Q1, the company's liquidity remains critical, underscoring the urgent need for substantial additional funding or a major partnership to avoid bankruptcy.
At the time of this filing, SGMO was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $56.1M. The 52-week trading range was $0.10 to $0.77. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.